Cohance Life's shares have experienced an 8% decline, returning to levels not seen since their recent peak. This downward trend may signal a potential change in investor sentiment towards the company.

Cohance Lifesciences' FY26 revenue dropped 13% YoY to INR 22.68 billion due to destocking, customer adjustments, and shipment delays. However, the company anticipates a recovery in H2 FY27, driven by growth in their CDMO and API segments, backed by new product launches and stronger customer relationships.

Goldman Sachs maintains a 'Buy' recommendation for Cohance Lifesciences, raising the price target to ₹525. The increased target suggests optimism about the company's potential growth.

Jefferies has downgraded Cohance Life to 'Underperform', citing weak Q4 results due to challenges in the Specialty Chemicals sector, management changes, a tough forecast for FY27, and projected EPS cuts of 14-17% for FY27-28. The new target price is set at ₹300.

Cohance Lifesciences reported a significant drop in Q4 net profit, with earnings falling from 1.2 billion rupees to 195 million compared to last year. The company also saw a decline in quarterly revenue, going from 8.4 billion rupees to 6.2 billion.

Cohance Lifesciences anticipates a low point in Q1 of FY27 for both revenue and EBITDA, but the stock is currently displaying signs of recovery after a downturn.

Cohance Lifesciences shares fluctuated between Rs. 463.5 and Rs. 505 on today's trading session, averaging at Rs. 484.25.

Cohance Lifesciences will reveal its Q1 results today, joining Dr Reddy's, Tata Power, Berger Paints, and Dixon in announcing their earnings for the same period.

Top investors have boosted their holdings in Indus Towers, Godrej Industries, Cohance Lifesciences, Poonawalla Fincorp, and Tanla Platforms for the fiscal year 2026. This move indicates positive market sentiments towards these companies, as suggested by Ashesha A's analysis of their valuations, analyst opinions, and growth prospects.

Cohance Lifesciences has appointed Umang Vohra as its new Chairman and CEO. With over 30 years of experience under his belt, including a tenure as the former MD and Global CEO of Cipla, Vohra is expected to bring significant industry knowledge and leadership to his new role.

Cohance Life's shares rose by 11% following the appointment of former Cipla CEO, Umang Vohra, as their new Executive Chairman, indicating investor confidence in his leadership skills.

Cohance Lifesciences has appointed former Cipla CEO, Umang Vohra, as their new Executive Chairman and Group CEO. This strategic move is aimed at boosting growth and improving strategic execution within the company.

Cohance confirms the recent surge in trading volume is attributed to broader market trends and not related to any imminent news or updates. Regular disclosures per UPSI guidelines are still being adhered to.